OHC is proud to be at the forefront in the use of immunotherapy, one of the newest approaches to treating cancer. Immunotherapy is a type of treatment that uses the body’s own immune system to fight cancer. The therapy mainly consists of stimulating the immune system to help it do its job more effectively. It can also involve adding things to your immune system, such as man-made proteins.
One of the newest, most exciting immunotherapies is chimeric antigen receptor (CAR) T-cell therapy, and the cancer experts at OHC are the first in the region to offer it to adults with blood cancers.
CAR-T is one of the most exciting and promising cancer treatment breakthroughs in recent years. CAR-T has shown dramatic results, with many patients previously considered terminal now in remission with good quality of life demonstrated for up to five years.
CAR-T is a type of immunotherapy that stimulates the body’s immune system to fight cancer. It uses genetically engineered immune T-cells to recognize specific proteins on tumor cells.
- Thousands of T-cells are extracted from the patient and modified in a lab to produce special receptors on their surface that fight and kill cancer cells.
- The modified cells are multiplied until there are millions and then infused back into the patient.
- The cells continue to then multiply on their own in the patient’s body. These cells will recognize and kill cancer cells, and help guard against recurrence.
OHC doctors are the only cancer experts in the region to offer this advanced treatment to adults at the Blood Cancer Center at The Jewish Hospital – Mercy Health, which is fully accredited to treat all blood cancers. All staff involved in prescribing, dispensing or administering CAR-T therapy have received special training to recognize and manage treatment side effects and nervous system toxicities that may occur.
OHC doctors use other types of immunotherapy, some in the form of a pill, some administered through an IV, and some in the form of a vaccine. These types of immunotherapies are used to treat these cancers:
- Head and neck cancer
- Merkle Cell
- Non-Hodgkin’s lymphoma
- Non-small-cell lung cancer
OHC is having great success with immunotherapies. In fact, OHC has patients who were diagnosed with stage 4 lung cancer that have been taking the drug Opdivo for more than six years. They report that the side effects are so minimal, they sometimes forget they have lung cancer.
There are still other immunotherapies that are only offered through clinical trials. As the region’s leader in cancer clinical trials, OHC provides patients with access to many of these trials.
For more information about immunotherapy, please click Request An Appointment or call 1-800-710-4674. If you are a new patient or would like a second opinion, we’d be happy to schedule an appointment with one of our doctors. If you would like information specifically regarding CAR-T therapy, click here.